Pharma Mar (OTCMKTS:PHMMF – Get Free Report) was down 8.3% on Tuesday. The company traded as low as $70.70 and last traded at $70.70. Approximately 250 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,597 shares. The stock had previously closed at $77.09.
Pharma Mar Stock Performance
The company’s 50 day moving average price is $92.23 and its 200 day moving average price is $93.05.
Pharma Mar Company Profile
Pharma Mar, SA is a Spanish biopharmaceutical company focused on discovering, developing and commercializing innovative medicines derived from marine organisms. The company specializes primarily in oncology and maintains a research platform dedicated to identifying novel compounds with potential anticancer activity.
Its principal products include Yondelis (trabectedin), an anticancer treatment used in certain cases of advanced soft-tissue sarcoma and ovarian cancer, and Zepzelca (lurbinectedin), a therapy developed for patients with metastatic small-cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
See Also
- Five stocks we like better than Pharma Mar
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.
